Nucleix
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Nucleix sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Nucleix: 5 sponsored US clinical trials, 1 recruiting.
Nucleix sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. The most-studied condition in this pipeline is Hematologic Neoplasms, with 1 trials.
Upper-quartile sponsor footprint
Nucleix sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Bladder EpiCheck Product Development Study
NCT07514143
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
NCT04968548
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
NCT06020807
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
NCT04264767
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
NCT02700464
Therapeutic Areas
What is open in the Nucleix pipeline
1 recruiting of 5 indexed (20% open); 3 completed (60%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Hematologic Neoplasms (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nucleix: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Nucleix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Nucleix page
5 registered trials is a research-attention snapshot, not an endorsement of Nucleix or any single study.
- 1 of Nucleix's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hematologic Neoplasms is the condition Nucleix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hematologic Neoplasms trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Nucleix pipeline card: 5 registered trials from official public datasets.Report a data error.